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Abstract 
Background: Idiopathic pulmonary fibrosis (IPF) identifies a specific lung disorder characterized by chronic, pro-
gressive fibrosing interstitial pneumonia of unknown etiology, which lacks effective treatment. According to the 
current pathogenic perspective, the aberrant proliferative events in IPF resemble those occurring during malignant 
transformation.
Main body: Receptor tyrosine kinases (RTK) are known to be key players in cancer onset and progression. It has been 
demonstrated that RTK expression is sometimes also altered and even druggable in IPF. One example of an RTK—the 
MET proto-oncogene—is a key regulator of invasive growth. This physiological genetic program supports embryonic 
development and post-natal organ regeneration, as well as cooperating in the evolution of cancer metastasis when 
aberrantly activated. Growing evidence sustains that MET activation may collaborate in maintaining tissue plasticity 
and the regenerative potential that characterizes IPF.
Conclusion: The present work aims to elucidate—by applying the logic of simplicity—the bio-molecular mecha-
nisms involved in MET activation in IPF. This clarification is crucial to accurately design MET blockade strategies within 
a fully personalized approach to IPF.
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Background
Idiopathic pulmonary fibrosis (IPF) is characterized 
by progressive scarring of the lungs ultimately leading 
to severe respiratory failure and death [1]. The median 
survival of patients is only 3  years following diagno-
sis [2], similar or worse than that of several oncologic 
diseases. Despite the fact that recently significant pro-
gress has been made in identifying of the bio-molecular 
mechanisms related to the development of IPF, a better 
understanding of disease pathogenesis is needed to iden-
tify more effective therapies and to improve patients’ 
outcome. According to the current pathogenic perspec-
tive, the aberrant proliferative events in IPF resemble that 
occuring during malignant transformation. Growing evi-
dence supports the cancer-like molecular nature of IPF 
and this intriguing hypothesis is now also being exploited 
for therapeutic purposes [3]. The discovery of pathogenic 
links between the two diseases may have practical conse-
quences in encouraging the use of cancer drugs for treat-
ing IPF. Receptor tyrosine kinases (RTK) are known to be 
key players in cancer onset and progression; it has also 
been demonstrated that the expression of some RTK fam-
ily members is also altered and even druggable in IPF [4, 
5]. The multi-kinase inhibitor—nintedanib—was initially 
developed for cancer, and has now been approved for the 
treatment of IPF thanks to the observation that targeted 
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MET proto-oncogene is a RTK that is a key regulator of 
invasive growth [7], which is the biological program that 
orchestrates dynamic changes in tissues leading to cell 
proliferation, survival and migration across the extracel-
lular matrix (ECM) and which can be inappropriately 
overexpressed in cancer spreading and metastatization. 
On the other hand, the MET-induced invasive growth is 
now emerging as potential target in IPF, although some 
issues require better understanding and clarification. 
Thus, this review aims to analyze the multiple facets of 
MET activation in cancer and IPF, under a context-spe-
cific perspective to the fibrotic disease.
The empirical evidence: MET structure and signaling
The MET proto-oncogene is a key regulator of the 
genetic program known as invasive growth. The MET 
gene, located on chromosome 7q31, encodes for the TK 
receptor for ‘Scatter Factor’ or Hepatocyte Growth Fac-
tor (HGF), which detects adverse micro-environmen-
tal conditions and drives cell invasion and metastasis 
through the transcriptional activation of the invasive 
growth signature, a genetic program also defined as the 
epithelial-mesenchymal transition (EMT) [8]. The lat-
ter includes cell–cell dissociation and scattering, migra-
tion, cellular proliferation, resistance to anoikis and 
angiogenesis. MET is now a prominent target in cancer 
therapy, with several compounds in active clinical devel-
opment (Table 1). Different strategies have been pursued 
to inhibit MET, each focusing on one of the sequential 
steps that regulate MET activation. Scatter factors (HGF 
and Macrophage-stimulating Protein-MSP) belong to 
the plasminogen family of proteins, which is defined by 
the presence of at least one characteristic domain known 
as the kringle domain (an 80 amino-acid double-looped 
structure formed by three internal disulphide bridges); a 
serine-protease domain and an activation segment that 
is located between the kringle and the protease domains. 
HGF and MSP are unique scatter factors because they 
lack proteolytic activity; they are secreted as single-
chain biologically inert glycoprotein precursors and are 
converted into their bioactive form in the extracellular 
environment by specific proteases, which break the bond 
between two positively charged aminoacids (Arg494–
Val495). The mature factors are heterodimers consisting 
of an α-chain and a β-chain held together by a disulphide 
bond. The MET receptor for HGF and the RON recep-
tor for MSP are single-pass, disulphide-linked α/β het-
erodimers that are formed by proteolytic processing of 
a common precursor in the post-Golgi compartment. 
In both receptors (which share 63  % overall homol-
ogy), the α-chains are completely extracellular, whereas 
the β-chains are transmembrane subunits that contain 
tyrosine kinase activity. The extracellular region of these 
receptors displays structural analogies with the extracel-
lular domains of semaphorins (a large family of secreted 
and membrane-bound proteins) and their receptors plex-
ins. The extracellular region contains the sema domain: a 
conserved sequence of about 500 amino acids compris-
ing an eight-cysteine peptide module that is convention-
ally termed MRS (MET-related sequence), together with 
three glycine-proline rich (G-P) repeats. The intracel-
lular domains include tyrosine kinase catalytic sites that 
are flanked by distinctive juxtamembrane and carboxy-
terminal sequences. Phosphorylation of MET on residues 
Tyr 1234 and Tyr 1235 within the catalytic sites results 
in positive modulation of enzyme activity, whereas phos-
phorylation of a serine residue in the juxtamembrane 
domain downregulates the kinase. After activation, 
MET elicits intramolecular phosphorylation of the other 
two critical tyrosine residues at the carboxy-terminal 
domains (Tyr 1349 and Tyr 1356), at the C-terminal of 
the α-chain: these two sites, together with the surround-
ing aminoacids, constitute the so-called “multifunctional 
docking site”, a motif which, when activated after phos-
phorylation, induces a series of biological processes that 
ultimately lead to invasive growth. The specificity of this 
unique response is determined by qualitative activation 
of specific pathways that are responsible for the onco-
genic and migratory effects of MET [for a full review see 
9–11], (Fig. 1). Moreover activation of the MET receptor 
is known to promote a cancer-associated thrombo-hem-
orrhagic syndrome that is mediated by transcriptional 
up-regulation of the pro-coagulation factors plasmi-
nogen activator inhibitor type-1 and cyclooxygenase-2 
[12]. In human tumors, MET activation can be induced 
through different mechanisms, namely: (i) MET over-
expression, related to: MET gene amplification; enhanced 
MET transcription; induction by other oncogenes such 
as RAS, RET; hypoxia-activated transcription; (ii) struc-
tural alteration, such as: point mutations which cause 
increased kinase activity; oncogene rearrangement 
(such as chromosomal translocation responsible for the 
Trp-MET fusion protein); abnormal post-translational 
processing resulting in a constitutively active molecule 
exposed on the cell membrane; impaired down-regula-
tion generally due to mutations that prevent binding of 
the Cbl ubiquitin ligase which is responsible for MET 
ubiquitination and endocytosis thus leading to increased 
receptor expression at cell surface and enhanced sig-
nal transduction. In addition, naturally truncated and 
active MET receptors have been detected in malignant 
human musculoskeletal tumors; (iii) HGF-independent 
autocrine-paracrine activation. In these contexts, parac-
rine activation—typical of physiological conditions—can 
become pathological in the presence of abnormal HGF 
production by mesenchymal cells. Autocrine activation 
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occurs when tumor cells aberrantly express both HGF 
and its receptor, as observed in rhabdomyosarcomas, 
gliomas, carcinomas of thyroid, breast and lung cancers, 
(iv) HGF-independent mechanisms. Moreover MET 
phosphorylation can also occur through transactivation 
by other membrane receptors, including adhesive recep-
tors such as CD44, integrins, signal transducing recep-
tors (RON, EGFR family members, FAS, plexin B9) [for 
a detailed review see 11, 13]. In addition, it has been 
demonstrated that MET activation can be mediated by 
an interaction between MET and microbes, including H. 
Pylori, associated with gastro-esophageal reflux disease 
which, in turn, is known to be implicated in the devel-
opment of IPF, giving rise to recurrent lung insult [14, 
15]. Notably, MET is expressed in stem and committed 
progenitor cells and the MET-driven invasive growth is 
usurped by cancer stem cells (CSC) [7]. As for normal 
tissues, tumors are structured according to a hierar-
chy, which includes two main components; thus tumors 
are composed of tumor-initiating cells (TICs), known 
as CSCs, which are the small fraction of cells within a 
tumor mass featuring self-renewal potential, capability of 
continuous proliferation and the ability to initiate tumor 
formation when transplanted. TICs also sustain tumor 
regeneration, growth and dissemination and can be con-
sidered the key target of cancer inhibition. Conversely, 
the vast majority of the tumor is constituted of cells with 
limited proliferative properties, which tend to aberrantly 
differentiate and ultimately die [16, 17]. Rapid progress 
has been made regarding CSC expression of metabolic 
regulation markers, growth factors, and transcription 
factors [18, 19]. A greater knowledge of the biological 
Table 1 Details on anti-MET agents already available in the clinical scenario for anticancer therapy
a For more details see: www.clinicaltrials.gow
Drug Target Cancer type References
Anti-MET monoclonal antibodies
 SAIT301 MET Advanced MET positive solid tumors [30]a
 ARGX-111 MET MET protein overexpressing advanced cancer [31]a
 MetMab (ornatuzumab) MET Advanced or metastatic solid tumors [32–37]a
 JNJ-61186372 MET-EGFR (bispecific ab) Advanced NSCLCs [38–40]a
 ABT-700 MET Advanced solid tumors
MET tyrosine kinase inhibitors
 PF-02341066 (crizotinib) MEK, ALK, ROS 1 (triple inhibitor) Advanced NSCLCs, gastric cancers, metastatic urothelial 
cancers,anaplastic large cell lymphoma, colorectal cancers, 
advanced relapsed/refractory solid tumors, primary CNS 
tumors
[41–43]a
 XL-184 (cabozantinib) MET, VEGFR2 (dual inhibitor) NSCLCs with brain metastasis, advanced cholangiocarcinoma, 
metastatic triple negative breast cancers, colorectal cancers, 
metastatic Merkel cell carcinoma, recurrent endometrial 
cancers, breast cancers with brain metastasis, metastatic 
renal cell carcinoma
[44–54]a
 AZD6094 (Volitinib) MET Gastric adenocarcinoma, papillary renal cell carcinoma [55–58]a
 GSK1363089 (Foretinib) MET, VEGFR2 (dual inhibitor) Papillary renal cell carcinoma, medulloblastoma, metastatic 
gastric cancers, hepatocellular carcinoma
[59–67]a
 AMG337 MET Advanced gastric and esophageal adenocarcinoma, advanced 
solid tumors
[68–72]a
 ARQ-197 (tivantinib) MET (non ATP-competitive) Relapsed/refractory multiple myeloma; locally advancer or 
metastatic colorectal cancers; metastatic triple negative 
breast cancers; childhood relapsed/refractory solid tumors; 
recurrent/metastatic head and neck cancers; gastric cancers; 
metastatic solid tumors; metastatic prostate cancers; meta-
static or locally advancer kidney cancers; mesothelioma; 
small cell lung cancers; hepatocellular carcinoma;
[73–90]a
 INC280 (capmatinib) MET NSCLCs; CRCs; HNSCC; advanced solid tumors, hepatocellular 
carcinoma; metastatic CRCs; metastatic renal cell carcinoma; 
recurrent glioblastoma; advanced or metastatic melanoma
[91, 92]a
 EMD 1204831 MET Advanced solid tumors; advanced hepatocellular carcinoma [93]a
 MGCD265 MEK, ALK (dual inhibitor) Advanced cancers [94, 95]a
 MK8033 MET, RON (ATP-competitive dual inhibitor) Advanced solid tumors [96]a
 PF-04217903 MET (ATP-competitive) Advanced cancers [97–99]a
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mechanisms responsible for maintaining the stem phe-
notype is required to understand more fully how the 
stem compartment sustains tumor persistence, and leads 
to recurrence after tumor dormancy and failed therapies. 
In this way, the clinical management and therapeutic 
options for cancer can be improved. The MET oncogene 
is crucial to sustain CSC and self-maintenance of tumors. 
A number of studies have documented the involve-
ment of MET in TIC plasticity [20–23] in several cancer 
types and in inducing CSC chemo- and radio-resistance 
[24–26]. In conclusion the MET-driven invasive growth 
is necessary for efficient cancer spreading as well as 
stemness properties. Due to its overlapping biological 
functions MET activation influences IPF development 
and progression. We and others have already reported 
that both myofibroblasts and epithelial cells of fibroblast 
foci in IPF harbor MET in its activated form [27, 28]. 
Although the anti-fibrotic effect of the MET-ligand HGF, 
is well known [11, 29], deregulation of the MET signaling 
cascade is clearly implicated in the development of IPF 
but its exact role remains to be clarified. 
Competing hypotheses: the role of MET in IPF
IPF is a proliferative disorder affecting the lungs, charac-
terized by aberrant deposition of ECM and consequent 
remodeling associated with the activation of fibroblasts 
as a response to still unknown injuries. IPF diagnosis is 
confirmed by histological identification of the usual 
interstitial pneumonia (UIP) pattern on surgical (and 
rarer transbronchial) biopsies, together with detection at 
high resolution (HR) computerized tomography (CT) 
scan of bibasilar reticular abnormalities (honeycombing 
pattern) with minimal or absent ground-glass opacities 
[1, 101, 102]. The key histological feature of IPF is repre-
sented by the so-called fibroblast foci (FF) defined as 
aggregates of actively proliferating fibroblasts and myofi-
broblasts. Activated fibroblasts express α-SMA (smooth 
muscle actin), accounting for to term “myofibroblasts”. In 
Fig. 1 MET signaling pathway in IPF. Enhanced MET activation controls genetic programs leading to cell growth, invasiveness and protection from 
apoptosis. For both the biological and therapeutic implications of MET activation in myofibroblasts in FF, its KRAS-driven pro-proliferating activity 
can be separated from the PI3CA-related pro-invasive role. The activity of branching morphogenesis depends on STAT family members, mainly 
STAT3 (Giordano et al. [100]). STAT3 is known to contribute to lung damage in IPF onset and progression (Pedroza et al. FASEB J 2016; 30(1):129–4)
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addition they secrete increased levels of ECM-degrading 
proteases (metalloproteinases MMP2, MMP3, MMP9), 
facilitating increased ECM turnover and altered ECM 
deposition; they also secrete growth factors (such as 
HGF, IGF, NGF, WNT1 and EGF) which can induce pro-
liferative signals within adjacent epithelial cells. Moreo-
ver activated fibroblasts behave as modulators of the 
immune response following tissue injury by secreting 
cytokines (e.g. IL-1) and chemokines (e.g. MCP1) [103–
107]. Activated fibroblasts/myofibroblasts can be found 
in wound healing processes and sclerosing tissue and as 
well as in cancers [108]. Through embryogenesis, cells 
start to move out from developing tissues in order to 
organize the structure of fetal organs. In a similar fash-
ion, in adult life, during wound healing and tissue repair 
processes, health cells migrate into the wound to recreate 
pre-existing tissue patterns [109]. The acquisition of cell 
motility is required but is not enough to sustain the 
whole process. Indeed cells need to trigger a number of 
biological programs, as well as to activate mitotic divi-
sions to repair injured tissues [110]. Thus embryogenesis, 
tissue repair after wound healing and cancer share simi-
lar mechanistic basis, since the same biological activi-
ties—cell proliferation, survival and migration, namely 
the Invasive Growth—are activated in both normal and 
malignant contexts. During wound healing repair activi-
ties as well as in cancer metastatic spreading, several 
cytokines are secreted in the reactive interstitial com-
partment. For instance interleukin-1 (IL-1) and 6 (IL-6), 
tumor necrosis factor alpha (TNF-α) and transforming 
growth factor beta (TGF-β) are known to induce the 
transcriptional up-regulation of HGF (in fibroblasts and 
macrophages) and MET (in epithelial cells) [111, 112]. 
HGF is also biologically activated, as demonstrated by 
the overexpression of proteases involved in pro-HGF 
activation [113, 114]. Moreover, HGF might be activated 
through an autocrine loop in stromal myofibroblasts. 
This mechanisms has been well demonstrated during 
tumor cell invasion [115] but can reasonably be signifi-
cant in wounds repair as well. Overall, this highly perfor-
mant HGF assures a proper activation of MET, which is, 
thus, involved in tissue protective physiological systems. 
These morphogenetic pathways trigger the EMT by acti-
vating biological processes such as cell motility and inva-
sion [116], known as invasive growth program. The 
aberrant activation of the above described wound healing 
machinery ultimately characterizes IPF onset and pro-
gression. Thus, HGF/MET-driven aberrant morphogene-
sis plays a crucial role not only in cancer but in IPF, as 
well. However it should be underlined that its activation 
and progression in IPF certainly differs from that in can-
cer, regarding both spatial and temporal characteristics. 
A proliferating tumor becomes malignant when 
neoplastic cells move to adjacent environments and settle 
in tissues and organs that are distant from the original 
site of growth. In IPF the actively proliferating FFs con-
trast with neighboring areas of relatively normal paren-
chyma and move from subpleural regions towards central 
areas. IPF is overall a lung-specific disease, defined by a 
centripetal track of disease progression in absence of dis-
tant cell scattering. The latter is a key difference with 
respect to scattering of malignant cells, which essentially 
means distant and peripheral dissemination. Further-
more IPF is a heterogeneous disease also in the age of 
lesions, meaning the stage of pathology in different lung 
parenchymal regions. Thus normal lung tissue is inter-
spersed with interstitial fibrosis, honeycomb cysts and 
fibroblast foci [1]. On the other hand, it is well known 
that most tumors tend to become more aggressive in 
clinical behavior over time, although this time course 
may be variable. During cancer progression, MET activa-
tion generally occurs as a late event, as a consequence to 
transcriptional up-regulation driven by unfavorable 
microenvironmental conditions, such as hypoxia or ion-
izing radiation [7, 117]. Sometimes, rapidly invasive can-
cers are diagnosed because of appearance of metastatic 
lesions in absence of a clearly detectable  pri-
mary mass. Among these highly invasive and malignant 
tumors, an extremely high mutational frequency of MET 
coding sequence has been reported; MET mutations have 
been biologically associated to the observed transformed 
phenotype [118]. The above described differences 
between IPF and cancer strictly reflect the differences of 
cell lineages. Indeed cancer is, by definition, a disease of 
genes, which evolves through a dynamic process of clonal 
expansion and selection in of advantageous somatic 
driver lesions [119, 120]. Each individual tumour is 
defined by a unique clonal evolution resulting from an 
intricate connection between genetic and non-genetic/
epigenetic factors, leading to phenotypic and genotypic 
heterogeneity. Among the diversity in tumor-cell popula-
tion, the CSC compartment brings about tumor mainte-
nance and progression [121]. MET-driven invasive 
growth is aberrantly activated in cancer, mainly as a late 
event, leading to distant dissemination and malignant 
progression. More recent studies have reported that MET 
amplified cancer clones are selected under therapeutic 
pressure in a context of molecularly heterogeneous 
lesions exposed to targeted therapies or radiotherapy [8, 
122–125]. In CSC, both the occurrence of genetic lesions 
(as amplification) and physiological expression of MET 
can contribute to tumorigenesis and therapeutic resist-
ance, by sustaining the invasive growth phenotype. On 
the other hand, myofibroblasts within FF in IPF are char-
acterized by cellular and genetic heterogeneity. Nota-
bly—very recently, Jones and colleagues elegantly 
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demonstrated that FFs in IPF identify—quite unexpect-
edly—morphologically complex 3D-structures, each 
independent from the others [126]. These findings 
strongly suggest that IPF onset relies on the aberrant 
local responses that are activated and lead to multifocal 
injuries. As a consequence diffuse cellular fate conversion 
and tissue plasticity are associated to IPF. During organ 
regeneration, MET physiological activation displays pro-
tective functions: epithelial cells located at the wound 
edges exploit invasive growth to enhance cellular division 
and repopulation of the injured areas [127–129]. When 
the damage inappropriately persists, as in IPF, the HGF/
MET pair actively contrasts myofibroblasts activation 
and the consequent associated abnormal deposition of 
extracellular matrix [130]. Moreover it is well known that 
semaphorins might activate MET in and HGF-independ-
ent manner. As already presented, MET and plexins share 
high homology at the extracellular sema domain. When 
MET oligomerizes with plexins, it can be activated by 
semaphorins, even in the absence of its ligand HGF [131, 
132]. Growing evidence sustains that semaphorins—and 
their ligands plexins—have a role in enhancing immune 
function and angiogenesis as well as in controlling lung 
fibrogenic diseases [133–136]. As a consequence, fibros-
ing settings, as IPF, which co-express both HGF and plex-
ins might feature even hyperactive invasive capacities.
Applying the razor: MET as an actionable target for IPF
In a complex and heterogeneous setting, which applies 
to IPF, the principle of pluralitas non est ponenda sine 
necessitate (Ockham’s razor, principle  attributed to 
the 14th century logician William of Ockham) can be 
applied to correctly understand the role of MET-driven 
invasive growth at disease onset. IPF resembles cancer 
in many MET-associated behaviors, such as invasive 
phenotype and pro-coagulant status. However dynam-
ics of malignant divergent clonal selective pressure and 
heterogeneity clearly differ from those occurring in IPF 
and impact on the biological significance of MET activa-
tion. The RTK MET is phosphorylated in myofibroblasts 
in FF: in a context-specific regulation of its expression, 
MET might become a functional marker of IPF and an 
actionable target. The cytogenetic heterogeneity, that is 
a hallmark of FF, can be exploited for therapeutic pur-
poses and already commercially available MET-inhib-
itors can be tested to interfere with IPF progression. 
MET-mediated events in IPF rely on qualitative differ-
ences among physiological signals, whereas no driver 
genetic lesions, causally implicated in the disease can be 
clearly demonstrated. Thus MET blockage falls among 
those therapeutic strategies aimed to impair the “aber-
rant recapitulation of developmental programs” as 
Selma and coll. already defined IPF [137]. A dynamic 
crosstalk between MET and developmental signaling 
pathways which are known to be activated in IPF is well 
documented. Among them the most relevant are those 
driven by Wnt/β-catenin and TGFβ cascades [116, 136]. 
The evolutionary conserved Wnt signaling canonical 
pathway is known to be a key player in maintaining tis-
sue homeostasis, cell proliferation and differentiation, 
and in regulating cell renewal and differentiation. Wnt 
signaling is also implicated in a variety of cancers [138, 
139]. Wnt/β-catenin pathway is expressed in the adult 
lung epithelium and overexpressed during inappropri-
ate EMT in IPF [116, 140]. Although intensive efforts 
have been made, the Wnt signaling pathway remains dif-
ficult to target. Tight cross-talk among MET and Wnt 
signaling is known in tissue morphogenesis as well as 
in several cancer types [141–144]. Conversely, an intri-
cate interaction between TGFβ and MET signaling is 
well discovered. The TGFβ superfamily is known to 
play a critical role in the regulation of cell differentia-
tion and proliferation. The TGF cascade mainly involves 
the activation of the cytoplasmic signaling molecules 
Smad2 and Smad3 for the TGF/activin pathway and 
Smad1/5/5/9 for the TGF/bone morphogenetic protein 
(BMP) pathway [145–149]. In particular the cross talk 
between TGFβ/BMP pathways is implicated in several 
biological programs and involved in a number of pro-
gressive disease, among which cancer [150–153]. The 
role of the TGFβ pathway has been extensively studied in 
IPF. Overexpression of its effects is induced by persistent 
injury and is, in turn, associated to the aberrant lung 
remodeling and fibrogenesis by activating myofibro-
blasts to produce extracellular matrix [130, 154]. Many 
drugs have been developed to target the TGFβ family 
signaling cascade [155]. In particular the FDA approved 
in 2014 the TGFβ1 inhibitor Pirfenidone for IPF therapy 
[156–159]. HGF can antagonize the TGFβ profibrotic 
phenotypes by several mechanisms, mainly by transcrip-
tional TGFβ down-modulation [160] and ERK-mediated 
inhibition of Smad proteins [161, 162]. Nevertheless, 
more recently it has been shown that overexpression of 
the HGF receptor MET together with CD44 isoform 6 
(CD44v6) sustains the TGFβ signaling in IPF through 
an autocrine loop [27]. Another relevant issue is that 
there is considerable experimental evidence that tissue 
hypoxia is associated with the onset of fibrosis. However, 
although chronic hypoxemia can clinically characterize 
IPF, the role of local hypoxia as a driver of the progres-
sive fibrotic nature of the disease has not been fully clari-
fied. Low oxygen tension has variable effects on cellular 
proliferation depending on the cell type. While arresting 
alveolar epithelial cell proliferation, low oxygen tension 
has been shown to promote normal fibroblast prolifera-
tion, leading to the possibility that hypoxia may promote 
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IPF fibroblasts proliferation [163–166]. It has been 
recently reported that a pathological feed-forward loop 
may exist in the IPF lung, in which hypoxia promotes 
IPF fibroblasts proliferation via stimulation of miR-210 
expression, which in turn worsens hypoxia [167]. More 
importantly, molecular links are beginning to emerge 
between hypoxia, EMT and stemness. During embryo-
genesis hypoxia contributes to the induction of niches 
that maintain pluripotent cells. During carcinogenesis, 
hypoxia has the potential to exert significant effect on 
the maintenance and evolution of cancer stem cells. 
Moreover solid tumor hypoxia is a well-known factor in 
tumor aggressiveness and invasive potential [168]. It is 
plausible that hypoxia-induced MET up-regulation may 
occur in IPF as well, and can cooperate in triggering the 
regenerative/reparative processes that define the disease 
onset and progression. This hypothesis questions the 
use of anti-angiogenic agents in IPF, as in cancer ther-
apy; deprivation of a blood supply, and thus of oxygen 
could in fact induce, besides the desirable tissue necro-
sis, a dangerous “invasive switch”. It would therefore be 
advisable to combine anti-angiogenic treatments (e.g. 
nintedanib) with an anti-MET agent to prevent these 
potential drawbacks. Regarding the rationale of MET 
therapeutic blockade in IPF, another key point must be 
underlined. Since IPF is, by definition, polyclonal, the 
reported MET activation may be independent of on 
the phenomena of oncogenic addiction associated with 
structural alterations related to cancer clonal evolution 
or—considering the role played by HGF—to ligand–
receptor autocrine circuits, which frees cells from the 
need for a paracrine supply of growth factor. In this per-
spective, cells undergoing EMT often take advantage of 
the physiological function of MET as an “expedience” 
[169] to gain a selective advantage in IPF progression.
Conclusion
The molecular pathways involved in the metastatic pro-
cess in cancer are shared with IPF. Among them the 
MET-driven invasive growth program plays a crucial role. 
As discussed above, MET activation governs a number 
of physiological and pathological processes that modu-
late dynamic changes and plasticity of tissues. If in can-
cer MET activation enables cells to overcome damage 
induced by targeted agents and ionizing radiation, there 
is enough evidence to sustain that in IPF the versatility of 
the MET-mediated biological responses may promote tis-
sue remodeling by integrating growth, survival and migra-
tion cues in response to abnormal environmental stimuli 
or cell-autonomous perturbations in absence of addiction 
phenomena. More likely, MET expression in myofibro-
blasts behaves as in cancer stem cells, where it sustains 
the inherent self-renewing, self-preserving and invasive 
growth phenotype [8, 19]. These notions indicate three 
clinical implications: (1) MET is a versatile candidate for 
targeted therapeutic intervention in IPF. (2) Targeted 
therapies against MET could be effective as a combinato-
rial approach to restrict disease progression, rather than 
being used as single front-line approaches. (3) Validation 
of MET expression as a biomarker is mandatory to devel-
oping therapies for IPF based on MET inhibition.
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